CD226 and hepatocellular carcinoma: Altogether, these clinical trials suggest that the TIGIT/DNAM-1 axis is indeed a target for the upcoming generation of ICIs, and a new therapeutic opportunity for the treatment of several tumor types, potentially including HCC [24].